Market closedNon-fractional
Harmony Biosciences/HRMY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Harmony Biosciences
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.
Ticker
HRMY
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
Plymouth Meeting, United States
Employees
246
Website
www.harmonybiosciences.com
HRMY Metrics
BasicAdvanced
$1.9B
Market cap
14.37
P/E ratio
$2.32
EPS
0.72
Beta
-
Dividend rate
Price and volume
Market cap
$1.9B
Beta
0.72
Financial strength
Current ratio
3.109
Quick ratio
2.931
Long term debt to equity
34.201
Total debt to equity
37.46
Interest coverage (TTM)
9.03%
Management effectiveness
Return on assets (TTM)
16.30%
Return on equity (TTM)
28.73%
Valuation
Price to earnings (TTM)
14.371
Price to revenue (TTM)
3.167
Price to book
3.66
Price to tangible book (TTM)
4.9
Price to free cash flow (TTM)
9.418
Growth
Revenue change (TTM)
30.92%
Earnings per share change (TTM)
-25.15%
3-year revenue growth (CAGR)
45.72%
3-year earnings per share growth (CAGR)
128.43%
What the Analysts think about HRMY
Analyst Ratings
Majority rating from 7 analysts.
HRMY Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$155M
-8.19%
Net income
$38M
43.98%
Profit margin
24.77%
56.87%
HRMY Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.56
$0.63
$0.45
$0.67
-
Expected
$0.63
$0.65
$0.48
$0.60
$0.01
Surprise
-11.46%
-3.08%
-6.01%
10.87%
-
HRMY News
AllArticlesVideos
HARMONY BIOSCIENCES TO REPORT SECOND QUARTER 2024 FINANCIAL RESULTS ON AUGUST 6, 2024
PRNewsWire·4 days ago
HARMONY BIOSCIENCES ACKNOWLEDGES U.S. FOOD & DRUG ADMINISTRATION (FDA) ACTION DENYING THE CITIZEN PETITION FOR WAKIX® (PITOLSIANT)
PRNewsWire·1 month ago
HARMONY BIOSCIENCES RECEIVES U.S. FOOD AND DRUG ADMINISTRATION APPROVAL FOR WAKIX® (PITOLISANT) IN PEDIATRIC PATIENTS WITH NARCOLEPSY
PRNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Harmony Biosciences stock?
Harmony Biosciences (HRMY) has a market cap of $1.9B as of July 27, 2024.
What is the P/E ratio for Harmony Biosciences stock?
The price to earnings (P/E) ratio for Harmony Biosciences (HRMY) stock is 14.37 as of July 27, 2024.
Does Harmony Biosciences stock pay dividends?
No, Harmony Biosciences (HRMY) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Harmony Biosciences dividend payment date?
Harmony Biosciences (HRMY) stock does not pay dividends to its shareholders.
What is the beta indicator for Harmony Biosciences?
Harmony Biosciences (HRMY) has a beta rating of 0.72. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Harmony Biosciences stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.